Are your V H H libraries fully humanized?

We offer both Synthetic Humanized libraries (built on human scaffolds with randomized CDRs) and Naïve libraries. The synthetic libraries yield leads that often require little to no further humanization.

Can V H Hs bind as tightly as IgGs?

Yes. Despite their small size, V H Hs from our libraries frequently achieve single-digit nanomolar or even picomolar affinity due to their high CDR3 diversity.

How do you handle half-life extension?

V H Hs clear rapidly. We can screen for Albumin-binding V H Hs concurrently to create bispecifics with extended serum half-life, or help you fuse leads to Fc domains.

What is the manufacturing yield?

V H Hs generally express at very high levels in microbial systems (g/L scale). We assess expression yield during the primary screening phase.

Premade Single Domain Antibody (SdAb) Library Screening Service

Screening Services Workflow Premade Libraries Cases Related Services Why Choose Us? FAQ

Creative Biolabs overcomes the limitations of conventional IgGs by offering high-diversity Single Domain Antibody (SdAb/ V_HH) screening. We leverage massive premade humanized and naïve V_HH libraries to discover ultra-stable, 15kDa binders that penetrate dense tissues, access concave active sites, and serve as robust building blocks for next-generation biologics.

Get Started - Request Your Quote Today

Small Format, Massive Access: Unlock Cryptic Epitopes with Functional V_HHs

Access hidden targets and build superior multispecifics with our premier Single Domain Antibody libraries.

Conventional antibodies (~150kDa) often fail to penetrate dense solid tumors or access the "canyon-like" active sites of enzymes and GPCRs due to steric hindrance. Creative Biolabs' SdAb Service solves this. By utilizing Single Domain Antibodies (V_HHs), which are one-tenth the size of an IgG, we enable you to target these undruggable epitopes. At Creative Biolabs, screening is a strategy engineered for developability. We don't just find V_HHs that bind; we find V_HHs that behave. Our premade libraries are engineered with humanized frameworks and extended CDR3 loops, screened via expert phage display strategies to deliver binders that combine the affinity of an IgG with the physical versatility of a small molecule.

Access Cryptic Epitopes
Long-CDR3 paratopes designed to bind deep enzymatic clefts and hidden pockets.

High Thermal Stability
Binders selected to withstand harsh manufacturing and conjugation conditions.

Modular Architecture
Ideal building blocks for Bispecifics, CAR-Ts, and ADCs.

Humanized Scaffolds
Libraries built on clinically validated frameworks to minimize immunogenicity.

Rapid Discovery
Streamlined prokaryotic expression workflows accelerate hit-to-lead times.

Design Your V_HH Strategy with Our Experts

How We Work

Inputs

Target name, Crystal structure (if available), Desired Epitope (e.g., Active site, Receptor interface), Modality goal.

Workflow

Fig.1 Antigen Design. (Creative Biolabs AI)

Antigen Design

Fig.2 Enrichment (Panning). (Creative Biolabs AI)

Enrichment (Panning)

Fig.3 Clone Screening. (Creative Biolabs AI)

Clone Screening

Fig.4 Functional Selection. (Creative Biolabs AI)

Functional Selection

Fig.5 Sequence Analytics. (Creative Biolabs AI)

Sequence Analytics

Fig.6 IgG Conversion. (Creative Biolabs AI)

IgG Conversion

Deliverables

Ranked V_HH sequences, epitope bins, kinetic data, and purified V_HH protein.

Discuss Your Screening Strategy with an Expert

Ready-to-Screen Antibody Libraries

We offer a curated selection of V_HH libraries optimized for stability, humanization, and epitope access.

Camel Llama Alpaca Humanized V_HH

Antibody Library ID	Display Technology	Library Format	Library Size
CaV_HHL-5	pIII-fusion, Phagemid Phage Display	Naïve V_HH	3.0×10¹⁰
CaV_HHL-S2 ☆Popular Choice	pIII-fusion, Phagemid Phage Display	Synthetic V_HH	5.4×10¹⁰

Find the Perfect V_HH Library for Your Target

Case Study: High-Diversity Libraries, High-Impact Outcomes

Screening for Cross-Species Reactive V_HH Binders

Project Goal

Development of a therapeutic antibody targeting a transmembrane receptor involved in hematopoiesis. Crucially, the client required high-affinity binding to both Human and Murine orthologs to enable direct efficacy studies in syngeneic mouse models.

Project Challenge

The target receptor exhibits significant sequence divergence between humans and rodents in the extracellular domain. Standard panning campaigns typically yield binders that are highly specific to the human antigen but fail to recognize the murine counterpart.

Our Solution

We implemented an Alternating Antigen Selection Strategy. By strictly alternating the antigen source between Human and Murine recombinant proteins across consecutive rounds of panning, we applied selective pressure to favor phage clones targeting evolutionarily conserved epitopes.

Key Results

Robust Enrichment & Diversity Significant enrichment signals were observed against both human and mouse targets compared to controls. Sequence analysis identified 10 distinct sequence families, ensuring a diverse pool of potential candidates.
Triple-Species Cross-Reactivity Soluble ELISA validation confirmed that all 10 unique V_HH candidates achieved specific binding not only to Human and Mouse orthologs but also to Cynomolgus targets.
High-Quality & Developability All candidates demonstrated high expression yields and purity. Crucially, the V_HHs retained full binding activity across all three species following tag cleavage and endotoxin removal, rendering them in vivo ready for immediate efficacy testing.

Related Services

Fig.16 Anti-peptide/protein antibody discovery. (Creative Biolabs AI)

Functional Human Antibody Discovery

Fig.16 Anti-peptide/protein antibody discovery. (Creative Biolabs AI)

Anti-Peptide/Protein Antibody Discovery

Fig.17 Anti-Cell-based target antibody discovery. (Creative Biolabs AI)

Anti-Cell-based Target Antibody Discovery

Fig.18 Bi-functional antibody discovery. (Creative Biolabs AI)

Bi-functional Antibody Discovery

Fig.19 Cell-internalizing antibody discovery. (Creative Biolabs AI)

Cell-Internalizing Antibody Discovery

Fig.20 Anti-epitope antibody discovery. (Creative Biolabs AI)

Anti-Epitope Antibody Discovery

Fig.22 Anti-disease-specific target antibody discovery. (Creative Biolabs AI)

Anti-Disease-Specific Target Antibody Discovery

Fig.21 Antibody discovery for immunotherapy. (Creative Biolabs AI)

Antibody Discovery for Immunotherapy

Why Choose Creative Biolabs for V_HH/SdAbs?

We combine the versatility of single-domain antibodies with the rigor of industrial-scale screening to deliver robust therapeutic building blocks.

Cryptic Epitope Access

Our library designs and screening strategies are specifically tuned to exploit the "finger-like" binding mode of V_HHs to hit hidden targets.

Stability-Driven Selection

We incorporate thermal and chemical stress tests directly into the binder validation process, ensuring your leads are stable and aggregation-resistant.

Modularity Mastered

V_HHs are perfect plug-and-play components for Bispecifics, CARs, and ADCs.

Weeks, Not Months

The high expression yields of V_HHs in E. coli or Yeast allow us to compress the discovery timeline significantly compared to mammalian IgG workflows.

Humanization Logic

Our synthetic libraries are built on validated humanized scaffolds, reducing the need for extensive downstream engineering.

Radical Transparency

You receive end-to-end data access, including NGS clonotype clustering and full sequence deliverables.

Book a Technical Consultation

Ready to move fast? Creative Biolabs will scope your target, advise on best library and protocol, and get screening up and running as soon as possible.

FAQ

Are your V_HH libraries fully humanized?
We offer both Synthetic Humanized libraries (built on human scaffolds with randomized CDRs) and Naïve libraries. The synthetic libraries yield leads that often require little to no further humanization.
Can V_HHs bind as tightly as IgGs?
Yes. Despite their small size, V_HHs from our libraries frequently achieve single-digit nanomolar or even picomolar affinity due to their high CDR3 diversity.
How do you handle half-life extension?
V_HHs clear rapidly. We can screen for Albumin-binding V_HHs concurrently to create bispecifics with extended serum half-life, or help you fuse leads to Fc domains.
What is the manufacturing yield?
V_HHs generally express at very high levels in microbial systems (g/L scale). We assess expression yield during the primary screening phase.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: